VP

Vestal Point Capital, LP

Diversified strategyHigh-turnover traderSector-focused

Total reported value

$3.6B

Reporting period: 2026-03-31 · Number of holdings: 90

Vestal Point Capital, LP disclosed 90 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $3.6B and a quarterly turnover rate of 103.4%.

Personality snowflake

Concentration
10.22
Portfolio Stability
100
Momentum/Contrarian
100
Sector conviction
100
Diversification
100
Sizing Uniformity
88.54

Recent moves

  • Add RVMD

    +705.1%　$207.5M

  • Trim 430

    -77.8%　-$129.1M

  • Trim ABVX

    -21.1%　-$89.2M

  • Add RGEN

    +1014.5%　$95.4M

  • Trim GMED

    -52.1%　-$58.7M

  • Trim TYRA

    -97.8%　-$61.7M

Holdings Map

New buyAddUnchangedTrim

Top 10 holdings by weight

Full holdings list this quarter

#TickerIssuerAsset SubclassWeightWeight ChangeShares Change4Q Trend
1RVMDRevolution Medicines INCStock-Healthcare6.46%+5.66%+705.08%
2BMRNBiomarin Pharmaceutical INCStock-Healthcare5.65%-0.41%+19.17%
3ABVXAbivax Sa-adrStock-Other4.67%-4.04%-21.05%
4NBIXNeurocrine Biosciences INCStock-Healthcare4.60%+4.60%NEW
5ARWRArrowhead Pharmaceuticals InStock-Healthcare3.99%+1.96%+152.78%
6ELVNEnliven Therapeutics INCStock-Other3.56%+1.55%-15.14%
7RGENRepligen CORPStock-Healthcare3.05%+2.59%+1014.46%
8BCAXBicara Therapeutics INCStock-Other3.02%+0.97%+51.75%
9NRIXNurix Therapeutics INCStock-Other2.82%—+38.59%
10APGEApogee Therapeutics INCStock-Other2.59%+1.18%+100.00%
11ASNDAscendis Pharma A/SStock-Other2.40%+1.13%+114.29%
12IMCRImmunocore Holdings Plc-adrStock-Other2.33%+1.64%+372.97%
13TSHATaysha Gene Therapies INCStock-Other2.25%—+30.91%
14DYNDyne Therapeutics INCStock-Other2.03%+1.95%+3233.33%
15SNYSanofi-adrStock-Healthcare1.89%+1.89%NEW
16BCRXBiocryst Pharmaceuticals INCStock-Other1.87%+1.27%+212.22%
17SRRKScholar Rock Holding CORPStock-Other1.82%+0.77%+89.20%
18✓ Immatics NVStock-Other1.70%—+0.82%
19BMYBristol-myers Squibb CoStock-Healthcare1.70%+1.24%+300.00%
20ALCAlcon Inc.Stock-Healthcare1.69%-1.27%-27.60%
21GLUEMonte Rosa Therapeutics INCStock-Other1.66%+1.25%+364.96%
22VERAVera Therapeutics INCStock-Other1.54%+0.59%+148.76%
23430Terns Pharmaceuticals INCStock-Other1.47%-4.71%-77.78%
24GMEDGlobus Medical INC - AStock-Healthcare1.47%-2.31%-52.12%
25BSXBoston Scientific CORPStock-Healthcare1.40%+1.40%NEW
26NUVLNuvalent Inc-aStock-Other1.38%+1.22%+947.21%
27COGTCogent Biosciences INCStock-Other1.32%+1.32%NEW
28ANROAlto Neuroscience INCStock-Other1.30%—-16.94%
29RAPPRapport Therapeutics INCStock-Other1.26%—+29.39%
30IRONDisc Medicine INCStock-Other1.25%—-4.76%
31UTHRUnited Therapeutics CORPStock-Healthcare1.24%+1.24%NEW
32CLDXCelldex Therapeutics INCStock-Other1.09%—+5.08%
334XC1Kalvista Pharmaceuticals INCStock-Other1.04%—-2.12%
34XENEXenon Pharmaceuticals INCStock-Other1.04%—+6.65%
35SLDBSolid Biosciences INCStock-Other1.01%—-14.02%
36DRUGBright Minds Biosciences INCStock-Other1.00%+1.00%NEW
37PTGXProtagonist Therapeutics INCStock-Other0.96%+0.96%NEW
38DNLIDenali Therapeutics INCStock-Other0.95%+0.69%+281.36%
39REGNRegeneron PharmaceuticalsStock-Healthcare0.86%+0.86%NEW
40WATWaters CORPStock-Healthcare0.83%+0.83%NEW
41VKTXViking Therapeutics INCStock-Healthcare0.83%+0.83%NEW
42INSPInspire Medical Systems INCStock-Healthcare0.78%+0.78%NEW
43✓ Crescent Biopharma INC.Stock-Other0.77%——
44TRVITrevi Therapeutics INCStock-Other0.72%+0.72%NEW
45LXEOLexeo Therapeutics INCStock-Other0.72%——
46SLNOEURSoleno Therapeutics INCStock-Other0.68%+0.68%NEW
47BBNXBeta Bionics INCStock-Other0.62%—+268.59%
48NKTRNektar TherapeuticsStock-Other0.57%+0.57%NEW
49CYTKCytokinetics INCStock-Healthcare0.55%+0.55%NEW
50AZNAstraZeneca PLCStock-Healthcare0.55%+0.55%NEW
1–50 of 90

Holding changes this quarter

Vestal Point Capital, LP's most significant position changes for 2026-03-31: Sold out: Invesco Qqq Trust Series 1 (QQQ); Sold out: Arcellx INC (ACLXGBX); New buy: Neurocrine Biosciences INC (NBIX); Sold out: Dexcom INC (DXCM); Sold out: Merck & Co. INC. (MRK).

Position changes disclosed by Vestal Point Capital, LP for the quarter ending 2026-03-31, including ticker, issuer, weight change, shares change, and action
#TickerIssuerWeight ChangeShares ChangeAction
1RVMDRevolution Medicines INC+5.7%+705.08%Add
2RGENRepligen CORP+2.6%+1014.46%Add
3ARWRArrowhead Pharmaceuticals In+2%+152.78%Add
4DYNDyne Therapeutics INC+2%+3233.33%Add
5IMCRImmunocore Holdings Plc-adr+1.6%+372.97%Add
6ELVNEnliven Therapeutics INC+1.6%-15.14%Trim
7BCRXBiocryst Pharmaceuticals INC+1.3%+212.22%Add
8GLUEMonte Rosa Therapeutics INC+1.3%+364.96%Add
9BMYBristol-myers Squibb Co+1.2%+300.00%Add
10NUVLNuvalent Inc-a+1.2%+947.21%Add
11APGEApogee Therapeutics INC+1.2%+100.00%Add
12ASNDAscendis Pharma A/S+1.1%+114.29%Add
13BCAXBicara Therapeutics INC+1%+51.75%Add
14SRRKScholar Rock Holding CORP+0.8%+89.20%Add
15DNLIDenali Therapeutics INC+0.7%+281.36%Add
16VERAVera Therapeutics INC+0.6%+148.76%Add
17BMRNBiomarin Pharmaceutical INC-0.4%+19.17%Add
18OLMAOlema Pharmaceuticals INC-1.2%-74.03%Trim
19ALCAlcon Inc.-1.3%-27.60%Trim
20TYRATyra Biosciences INC-2.1%-97.77%Trim
21GMEDGlobus Medical INC - A-2.3%-52.12%Trim
22ABVXAbivax Sa-adr-4%-21.05%Trim
23430Terns Pharmaceuticals INC-4.7%-77.78%Trim
24QQQInvesco Qqq Trust Series 1—EXITSold out
25ACLXGBXArcellx INC—EXITSold out
26NBIXNeurocrine Biosciences INC—NEWNew buy
27DXCMDexcom INC—EXITSold out
28MRKMerck & Co. INC.—EXITSold out
29ABTAbbott Laboratories—EXITSold out
30SNYSanofi-adr—NEWNew buy
31BSXBoston Scientific CORP—NEWNew buy
32JAZZJazz Pharmaceuticals plc—EXITSold out
33DAWNGBXDay One Biopharmaceuticals I—EXITSold out
34COGTCogent Biosciences INC—NEWNew buy
35UTHRUnited Therapeutics CORP—NEWNew buy
36AXSMAxsome Therapeutics INC—EXITSold out
37DRUGBright Minds Biosciences INC—NEWNew buy
38PTGXProtagonist Therapeutics INC—NEWNew buy
39REGNRegeneron Pharmaceuticals—NEWNew buy
40WATWaters CORP—NEWNew buy
41VKTXViking Therapeutics INC—NEWNew buy
42INSPInspire Medical Systems INC—NEWNew buy
43TRVITrevi Therapeutics INC—NEWNew buy
44SLNOEURSoleno Therapeutics INC—NEWNew buy
45LNTHLantheus Holdings INC—EXITSold out
46ZYMEZymeworks INC—EXITSold out
47NKTRNektar Therapeutics—NEWNew buy
48CYTKCytokinetics INC—NEWNew buy
49AZNAstraZeneca PLC—NEWNew buy
50UPBUpstream Bio INC—EXITSold out

FAQ

What is Vestal Point Capital, LP and what type of investor is it?
Vestal Point Capital, LP is a investment manager that files SEC Form 13F quarterly, disclosing its U.S. public equity holdings to regulators. As of the most recent reporting period (2026-03-31), the firm manages a tracked equity portfolio valued at approximately $3.6B, spread across 90 disclosed positions.
What are Vestal Point Capital, LP's largest equity positions?
Based on the latest 13F filing, Vestal Point Capital, LP's top holdings by market value are: 1. Revolution Medicines INC (RVMD) — $231.0M (6.5%) 2. Biomarin Pharmaceutical INC (BMRN) — $202.0M (5.7%) 3. Abivax Sa-adr (ABVX) — $167.0M (4.7%) 4. Neurocrine Biosciences INC (NBIX) — $164.7M (4.6%) 5. Arrowhead Pharmaceuticals In (ARWR) — $142.6M (4.0%)
What changes did Vestal Point Capital, LP make in its most recent portfolio filing?
In the latest reported quarter, Vestal Point Capital, LP made 50 notable position adjustments: 16 new positions were initiated, 16 existing holdings were added to, 7 positions were partially reduced, and 11 were completely exited. The largest of these moves: Sold out: Invesco Qqq Trust Series 1 (QQQ); Sold out: Arcellx INC (ACLXGBX); New buy: Neurocrine Biosciences INC (NBIX); Sold out: Dexcom INC (DXCM); Sold out: Merck & Co. INC. (MRK)
What sectors does Vestal Point Capital, LP focus on?
Vestal Point Capital, LP is concentrated in the following sectors based on its current disclosed equity portfolio: • Health Care: 100.0%